Heart disease in systemic sclerosis

Janosik, Denise L.; Osborn, Thomas G.; Moore, Terry L.; Shah, Dipti G.; Kenney, Richard G.; Zuckner, Jack

doi:10.1016/0049-0172(89)90032-2

Cited by 85 publications

(42 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, 60% of deaths in these patients are secondary to heart or lung involvement [21] and significant cardiac abnormalities are present in more than half of patients at autopsy [22]. Cardiac involvement may include myocardial disease, pericardial disease, conduction system disease, or arrhythmia [23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of cardiac laboratory markers in patients with systemic sclerosis

Montagnana

Lippi

Volpe

et al. 2006

Clinical Biochemistry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of cardiac laboratory markers in patients with systemic sclerosis

Montagnana

Lippi

Volpe

et al. 2006

Clinical Biochemistry

View full text Add to dashboard Cite

“…Primary cardiovascular manifestations of SSc include pericardial disease, myocardial disease, conduction abnormalities, and cardiac arrhythmias (Janosik et al 1989). In our patient, pre-transplant chest radiograph did not show any abnormal findings, but electrocardiogram demonstrated sinus tachycardia and low QRS voltage, and the BNP level was high.…”

Section: Discussionmentioning

confidence: 99%

“…It is well known that high-dose cyclophosphamide can cause an acute form of cardiotoxicity within 10 days of administration (Gharib and Burnett 2002). Furthermore, cardiovascular manifestations including pericardial disease, myocardial disease, and arrhythmias frequently occur in patients with SSc (Janosik et al 1989). In general, eligibility criteria for PBSCT require preserved cardiac function, defined as left ventricular ejection fraction (LVEF) more than 50% (Nishio et al 2001;Itoh et al 2004;Tang et al 2004).…”

mentioning

confidence: 99%

Successful Autologous Peripheral Blood Stem Cell Transplantation Using Thiotepa in a Patient with Systemic Sclerosis and Cardiac Involvement

Komatsuda

Kawabata

Horiuchi

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

A 19-year-old man with systemic sclerosis (SSc) was hospitalized for autologous peripheral blood stem cell transplantation (auto-PBSCT) due to progressive scleroderma and cardiac involvement despite conventional treatment. During the administration of cyclophosphamide (60 mg/kg/day for 2 days) for mobilization and collection of CD34 + selected peripheral blood stem cells, he developed congestive heart failure. Echocardiogram showed hypokinetic asynergy from the septum to posterior wall, which might indicate underlying cardiac damage. We were also concerned about the risk of high-dose cyclophosphamide-induced cardiotoxicity. Since the dose-limiting toxicity of thiotepa, an alkylating agent, is myelosuppression, and cardiac toxicity due to thiotepa is less common, we used a conditioning regimen consisting of thiotepa (10 mg/kg/day, day -5) and lowdose cyclophosphamide (50 mg/kg/day, days -3 and -2), instead of the conventional highdose cyclophosphamide (50 mg/kg/day × 4 days/course). The post-transplant course was uneventful, and the modified Rodnan skin thickness score improved from 32 to 15. The present case report demonstrates that thiotepa can be employed as a conditioning regimen for auto-PBSCT in SSc patients with cardiac involvement in order to reduce cyclophosphamide-induced cardiotoxicity.autologous peripheral blood stem cell transplantation (PBSCT); cardiotoxicity; cyclophosphamide; systemic sclerosis; thiotepa

show abstract

“…[27]). Isolierte Perikarditiden sind deutlich seltener als beim SLE [28]. Auch eine eher indirekte Auswirkung auf das kardiovaskuläre System stellt die sog.…”

Section: Systemische Skleroseunclassified

Das Herz bei rheumatologischen Erkrankungen

Specker

2007

Internist

View full text Add to dashboard Cite

As systemic immunological disorders inflammatory rheumatic diseases potentially involve organs and structures beyond the musculo-skeletal system including skin and blood vessels. Various neurological, renal, pulmonary, hematological and cardiac manifestations contribute to the broad clinical picture of connective tissue diseases and vasculitides. Regarding cardiac disease all structures of the heart may be affected. Pericarditis in lupus, mitral valve changes in the antiphospholipid syndrome, myocarditis and coronary artery stenosis in the systemic vasculitides are typical examples in systemic rheumatic diseases. Beyond this, pulmonary hypertension in systemic sclerosis or congenital heart block in newborns of lupus patients are further cardiac issues. Since better treatment options led to more long-lasting courses in connective tissue diseases, cardiovascular complications as a consequence of chronic disease- and therapy-related damage gain increasing attention.

show abstract

Heart disease in systemic sclerosis

Cited by 85 publications

References 40 publications

Evaluation of cardiac laboratory markers in patients with systemic sclerosis

Evaluation of cardiac laboratory markers in patients with systemic sclerosis

Successful Autologous Peripheral Blood Stem Cell Transplantation Using Thiotepa in a Patient with Systemic Sclerosis and Cardiac Involvement

Das Herz bei rheumatologischen Erkrankungen

Contact Info

Product

Resources

About